Sunitinib

Drug Profile

Sunitinib

Alternative Names: PHA-290940; PHA-290940AD; PNU-290940; PNU-290940AD; SU-011248; SU-11248; SU-11428; Sunitinib malate; Sutent

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Pfizer
  • Developer Australasian Sarcoma Study Group; Cancer Research UK; Case Comprehensive Cancer Center; Clatterbridge Cancer Centre NHS Foundation Trust; Hoosier Cancer Research Network; Korean Urological Oncology Society; Memorial Sloan-Kettering Cancer Center; Ohio State University; Pfizer; University of Michigan Comprehensive Cancer Center; University of Texas M. D. Anderson Cancer Center; US Oncology Research
  • Class Amides; Antineoplastics; Ethylamines; Fluorobenzenes; Indoles; Pyrroles; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Colony stimulating factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastrointestinal stromal tumours; Renal cell carcinoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastrointestinal stromal tumours; Pancreatic cancer; Renal cell carcinoma
  • Phase II Bladder cancer; Malignant melanoma; Oesophageal cancer; Prostate cancer; Thyroid cancer
  • Phase I/II Soft tissue sarcoma
  • No development reported Germ cell and embryonal neoplasms; Hepatocellular carcinoma
  • Discontinued Acute myeloid leukaemia; Breast cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Urogenital cancer

Most Recent Events

  • 31 Jan 2017 Pfizer withdraws a phase II trial prior to enrollment with recent advances in immunotherapy scientific question not significant in Malignant melanoma (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (NCT02400385)
  • 24 Jan 2017 Pfizer and Hoosier Cancer Research Network plan a phase II trial for Renal cell carcinoma (Combination therapy, Metastatic disease) in USA (NCT03035630)
  • 01 Jan 2017 Roche completes a phase II trial in Renal cell carcinoma (Metastatic, Second line therapy or greater) in Italy (EudraCT2012-000473-23)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top